|
|
De-risking the development programs of CETP inhibitors after the torcetrapib failure: Endothelial function & blood pressure
|
|
|
|
HDL : a novel target in prevention ?
|
|
|
|
Relationship Between Changes in LDL-C and HDL-C Levels and CHD Risk
|
|
|
|
Coronary Heart Disease and HDL-C
|
|
|
|
Reduced HDL is associated with increased CV risk – despite intense statin therapy
|
|
|
|
HDL-Raising Therapies on the Horizon
|
|
|
|
Schematic Overview of Lipoprotein Metabolism
|
|
|
|
Torcetrapib in High-risk Patients : ILLUMINATE Study
|
|
|
|
Torcetrapib causes Endothelial Dysfunction independent of CETP inhibition
|
|
|
|
CETP Inhibition and Endothelial Function
|
|
|
|
dal-VESSEL : Study Design
|
|
|
|
dal-Vessel: ABPM
|
|
|
|
dal-Vessel: baseline FMD
|
|
|
|
HDL as a Therapeutic Target
|
|
Prof. John Deanfield
Deanfield (PPTX 1.7MB)
Share this page with your colleagues and friends: